BBH — VanEck Biotech ETF price, holdings and performance
VanEck Biotech ETFVanEck Biotech ETF (NASDAQ: BBH) is an exchange-traded fund. QuoTrend tracks its price, holdings, performance, fund flows and news.
Latest market price
219.52
+2.94+1.36%
TA
Loading chart...
Fund Snapshot
| Category | - | Asset Type | Equity | Tags | healthcare | Return% 1Y | 38.21% | Total Holdings | 25 | Perf Week | 5.37% |
| Sponsor | VanEck | ETF Type | Tags | sector | Return% 3Y | 11.74% | AUM | $421.68M | Perf Month | 3.07% | |
| Fund Family | Bond Type | Tags | - | Return% 5Y | 1.34% | NAV/sh | Perf Quarter | 16.79% | |||
| Index | - | Average Maturity | Tags | - | Return% 10Y | 52W High | 219.52 0.00% | Perf Half Y | 11.20% | ||
| Index Weighting | Commodity Type | Tags | - | Return% SI | 52W Low | 158.58 38.43% | Perf YTD | 14.44% | |||
| Active/Passive | Quant Type | Tags | - | Flows% 1M | 2.35% | Volatility | 1.40% 1.18% | Perf Year | 37.31% | ||
| Dividend TTM | 0.96 (0.44%) | ESG Type | Tags | - | Flows% 3M | -1.67% | ATR (14) | 3.36 | Perf 3Y | 37.30% | |
| Dividend Ex-Date | Dec 22, 2025 | Dividend Type | Sector/Theme | Flows% YTD | 0.21% | RSI (14) | 68.91 | Perf 5Y | 4.63% | ||
| Dividend Gr. 3/5Y | - | Structure Type | Region | Flows% 1Y | Beta | 0.68 | Perf 10Y | 89.77% | |||
| Expense | 0.35% | Growth/Value | SMA20 | 5.05% | Flows% 3Y | Rel Volume | 1.02 | Prev Close | 216.58 | ||
| Inverse/Leveraged | Market Cap | SMA50 | 8.75% | Flows% 5Y | Avg Volume | 5.08K | Price | 219.52 | |||
| IPO Date | Dec 20, 2011 | Option/Short | Yes / Yes | SMA200 | 12.81% | 52W Range % | 100% | Volume | 5,178 | Change | 1.36% |
Assets Under Management
● Assets Under Management
Latest News
Aug-07-26
Aug-05-26
Aug-05-2603:02PM
Jul-29-26
Jul-25-26
Jul-22-26
Jul-19-26
Jul-17-26
Jul-14-26
Jul-14-2603:41PM
Jul-13-26
Jul-11-26
Jul-10-26
Jul-08-26
Jul-04-26
Jul-02-26
Jun-29-26
Fund
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Ownership
Per-holder 13F data isn't yet ingested for ETFs — coming with the next data layer expansion. Aggregate ownership shown above.